WuXi AppTec (Shanghai) Co

Activities: Research & Development

Trending Articles

  1. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Indian government bans three medicines owing to health risks Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
  4. Dickson achieves ISO 14001 certification ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
  5. The key role of IVDs in healthcare: challenges to commercialisation and access In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Contamination Control

WuXi AppTec opens aseptic filling line at Wuxi City site

Hosting an annual capacity of 9 million units, the line is poised to further bolster the company’s sterile platform capabilities
Manufacturing

WuXi AppTec triples peptide manufacturing capacity and launches the new Taixing API manufacturing site

Expansion boosts solid-phase peptide synthesis total reactor volume to 32,000 L in response to surging demand
Manufacturing

AtkinsRéalis awarded engineering design services contract for API manufacturing facility in Singapore

When completed, the Singapore site will play a critical role in WuXi AppTec’s global network across Asia, Europe and North America, meeting the growing demand from multinational customers and strengthening collaborations with a wide range of partners
Manufacturing

WuXi debuts high potency sterile injectable manufacturing line

The new HP injectable manufacturing line, with an annual capacity of 12 million units, further enhances the company’s manufacturing capabilities
Manufacturing

WuXi STA adds L reactors at Changzhou campus

The total reactor volume of the Solid Phase Peptide Synthesisers (SPPS) at WuXi TIDES has increased to over 10,000 L
Manufacturing

Wuxi STA's continuous manufacturing line under operation

This new CM line provides global customers an enhanced oral drug development solution, enabling higher yields and shortened timelines to market
Manufacturing

WuXi STA sites receive top EcoVadis scores

Through the rating scorecards, EcoVadis provides benchmarks for rated companies in their industry to drive global supply chain sustainability
Subscribe now